Advertisement
Singapore markets closed

  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     

  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     

  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     

  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     

  • Bitcoin USD

    57,715.79
    +1,208.80 (+2.14%)
     

  • CMC Crypto 200

    1,197.78
    -10.92 (-0.90%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • Dow

    39,375.87
    +67.87 (+0.17%)
     

  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     

  • Gold

    2,399.80
    +30.40 (+1.28%)
     

  • Crude Oil

    83.44
    -0.44 (-0.52%)
     

  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     

  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

Qiagen Q3 profit down 38% but raises full-year outlook

Reuters
·1-min read
FILE PHOTO: Health Testing company Qiagen, in Hilden

FRANKFURT (Reuters) - U.S.-German biotechnology company Qiagen NV said on Monday that its third-quarter net profit dropped 38%, but it raised its outlook for the full year.

Profit slumped in the quarter to $82 million from $133 million a year ago.

It said it was raising its outlook due to strong results in the first nine months and the outlook for the full year.

It now expects sales of $2.25 billion, up from a previous outlook for at least $2.2 billion.

Last month, The Wall Street Journal reported that California-based diagnostics company Bio-Rad Laboratories was in talks to merge with Qiagen.

(Reporting by Patricia Weiss; writing by Tom Sims; editing by Chris Reese)